Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets
Lorcaserin is a serotonergic agonist specific to the 5-hydroxytryptamine 2c receptor (5-HT2CR) that is FDA approved for the long-term management of obesity with or without at least one weight-related comorbidity. Lorcaserin can restrain patients’ appetite and improve insulin sensitivity and hyperins...
Enregistré dans:
Auteurs principaux: | Muhan Jing, Shanshan Wang, Ding Li, Zeyu Wang, Ziwen Li, Yichen Lu, Tong Sun, Chen Qiu, Fang Chen, Haijuan Yu, Wei Zhang |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/adfc739abd40432680c62a204c56bcf9 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
par: Hurt RT, et autres
Publié: (2018) -
Gαi/o-coupled Htr2c in the paraventricular nucleus of the hypothalamus antagonizes the anorectic effect of serotonin agents
par: Eun-Seon Yoo, et autres
Publié: (2021) -
Structural Basis of Type 2 Secretion System Engagement between the Inner and Outer Bacterial Membranes
par: Iain D. Hay, et autres
Publié: (2017) -
Diabetic Retinopathy and Insulin Insufficiency: Beta Cell Replacement as a Strategy to Prevent Blindness
par: Eli Ipp
Publié: (2021) -
Lorcaserin for weight management
par: Taylor JR, et autres
Publié: (2013)